<DOC>
	<DOCNO>NCT01010802</DOCNO>
	<brief_summary>The purpose study determine whether recombinant human Erythropoietin ( EPOrh ) safe treatment patient Parkinson 's Disease .</brief_summary>
	<brief_title>Safety Study Erythropoietin ( EPO ) Parkinson 's Disease</brief_title>
	<detailed_description>After onset Parkinson 's Disease ( PD ) - spite use medication constitute symptomatic treatment- disease worsen inevitable progression , thus cause complication lead loss patient´s manual skill independent gait . At present , treatment PD use medication base dopamine precursor dopaminergic agonist disease advance , symptom respond dopaminergic stimulation appear . For reason , priority find way focus neuroprotection course disease . There evidence neuroprotecting therapeutic alternative substance erythropoietin ( EPO ) . Positive result neuroprotective/neurotrophic efficacy EPO neurological psychiatric disease obtain treatment trial , nevertheless , indispensable demonstrate propose medication dose 's well tolerated PD patient .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Hohen Yahr´s Scale I III One year evolution PD , Good response levodopa ( 30 % change ) value motor UPDRS An acceptable general health status , Chronic psychiatric neurological disease . Previous polyglobulin Hematocryte , inferior 50</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Neuroprotection</keyword>
	<keyword>Parkinson Disease</keyword>
	<keyword>Erythropoietin</keyword>
</DOC>